HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
Khan
Omar
O
Laboratory of Cancer Biology, Medical Sciences Division, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Fotheringham
Susan
S
Wood
Victoria
V
Stimson
Lindsay
L
Zhang
Chunlei
C
Pezzella
Francesco
F
Duvic
Madeleine
M
Kerr
David J
DJ
La Thangue
Nicholas B
NB
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D001706:Biopsy; D045744:Cell Line, Tumor; D017322:Clinical Trials, Phase II as Topic; D045643:DNA Repair Enzymes / Q000235:genetics / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D015415:Biomarkers; D004268:DNA-Binding Proteins; D056572:Histone Deacetylase Inhibitors; C513287:RAD23B protein, human; D034741:RNA, Small Interfering; D046988:Proteasome Endopeptidase Complex; D045643:DNA Repair Enzymes